Zimbabwe has rejected a substantial US health deal worth 367 million US dollars (£272m) over five years over the United States' demand for confidential data.
This move became public following a official document from December was leaked, which showed Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official spokesman has since stated that the US was seeking biological samples for scientific study and commercial purposes but was unwilling to share the benefits from any future treatments.
"We will now turn to the challenging and unfortunate task of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided over $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for continued negotiations to find a deal suitable to both sides so the nation's critical HIV programme can be sustained.
Wider Implications
This rejection follows a similar situation in Kenya, where a high court halted a related health funding agreement after legal challenges were raised about the security of Kenyans' medical information.
Since resuming office recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had overseen assistance for the American government, but Trump claimed its spending was "inefficient" and his administration was pursuing direct bilateral deals to boost transparency and accountability.
According to reports, Sixteen African countries have so far agreed to these new agreements, constituting over $18.3bn of fresh investment.
Details of the Rejected Deal
The money for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation could have provided immense advantages for the people of Zimbabwe, especially the 1.2 million currently on antiretroviral therapy through US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the arrangement was "unfair".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, without any corresponding guarantee of access to any medical innovations – such as new medicines or tests – that could result from that provided information," his statement read.
"Put simply, our nation would supply the basic resources for medical research without any assurance that the end products would be accessible to our population should a new pandemic emerge."
Sovereignty and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending structures previously set up through the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework created to manage future global health emergencies.
"This framework is intended to guarantee that when a nation contributes its samples, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
The government's concerns over the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome continued discussions with our American counterparts on how future co-operation could be structured in a manner that respects the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body expressed it acknowledged the official position, but suggested that talks must proceed since a large portion of the country's HIV programmes relied on foreign aid.
"In cases where technical issues exist, such as those involving data governance or agreement terms, these can often be resolved through detailed discussion and negotiated safeguards," the group commented.
The situation emphasises the continuing tensions between accepting crucial international aid and protecting national sovereignty in an increasingly data-driven world.